Vazvaei-Smith F, Li W, Barnaby O, Bhardwaj S, Dong J, Dumont C
AAPS J. 2025; 27(2):57.
PMID: 40069400
DOI: 10.1208/s12248-025-01033-w.
Vermillion M, Murakami E, Ma B, Pitts J, Tomkinson A, Rautiola D
Sci Transl Med. 2021; 14(633):eabl8282.
PMID: 34968150
PMC: 8961622.
DOI: 10.1126/scitranslmed.abl8282.
Cirrincione L, Podany A, Havens J, Bares S, Dyavar S, Gwon Y
J Antimicrob Chemother. 2020; 75(5):1242-1249.
PMID: 32065631
PMC: 7177476.
DOI: 10.1093/jac/dkaa016.
Song Y, Zhang J, Li D
Micromachines (Basel). 2018; 8(7).
PMID: 30400393
PMC: 6190343.
DOI: 10.3390/mi8070204.
Seifert S, Chen X, Meditz A, Castillo-Mancilla J, Gardner E, Predhomme J
AIDS Res Hum Retroviruses. 2016; 32(10-11):981-991.
PMID: 27526873
PMC: 5067852.
DOI: 10.1089/AID.2016.0008.
Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy.
Zehnacker L, Abe E, Mathez D, Alvarez J, Leibowitch J, Azoulay S
AIDS Res Treat. 2014; 2014:724958.
PMID: 25431661
PMC: 4241735.
DOI: 10.1155/2014/724958.
Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients.
Domingo P, Gracia Mateo M, Pruvost A, Torres F, Salazar J, Gutierrez M
PLoS One. 2013; 8(6):e67035.
PMID: 23840581
PMC: 3694125.
DOI: 10.1371/journal.pone.0067035.
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Jackson A, Watson V, Back D, Khoo S, Liptrott N, Egan D
J Acquir Immune Defic Syndr. 2011; 58(5):450-7.
PMID: 21926632
PMC: 3594701.
DOI: 10.1097/QAI.0b013e3182364c67.
Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.
Bazzoli C, Benech H, Rey E, Retout S, Salmon D, Duval X
Antimicrob Agents Chemother. 2011; 55(7):3423-31.
PMID: 21576446
PMC: 3122424.
DOI: 10.1128/AAC.01487-10.
Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
Hirt D, Ekouevi D, Pruvost A, Urien S, Arrive E, Blanche S
Antimicrob Agents Chemother. 2011; 55(6):2961-7.
PMID: 21464249
PMC: 3101430.
DOI: 10.1128/AAC.01377-10.
Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.
Domingo P, Cabeza M, Pruvost A, Torres F, Salazar J, Gutierrez M
Antimicrob Agents Chemother. 2011; 55(4):1428-35.
PMID: 21282454
PMC: 3067160.
DOI: 10.1128/AAC.01589-10.
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Hawkins T, Veikley W, Durand-Gasselin L, Babusis D, Reddy Y, Flaherty J
Antimicrob Agents Chemother. 2011; 55(4):1549-55.
PMID: 21282432
PMC: 3067129.
DOI: 10.1128/AAC.00910-10.
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Molto J, Valle M, Back D, Cedeno S, Watson V, Liptrott N
Antimicrob Agents Chemother. 2010; 55(1):72-5.
PMID: 20937791
PMC: 3019627.
DOI: 10.1128/AAC.00789-10.
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet A
Clin Pharmacokinet. 2009; 49(1):17-45.
PMID: 20000887
DOI: 10.2165/11318110-000000000-00000.
Protein versus DNA as a marker for peripheral blood mononuclear cell counting.
Jansen R, Rosing H, Schellens J, Beijnen J
Anal Bioanal Chem. 2009; 395(3):863-7.
PMID: 19685233
PMC: 2745619.
DOI: 10.1007/s00216-009-3022-3.
Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.
Durand-Gasselin L, Van Rompay K, Vela J, Henne I, Lee W, Rhodes G
Mol Pharm. 2009; 6(4):1145-51.
PMID: 19545170
PMC: 2777719.
DOI: 10.1021/mp900036s.
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, Ayen R
Antimicrob Agents Chemother. 2009; 53(5):1937-43.
PMID: 19273671
PMC: 2681534.
DOI: 10.1128/AAC.01064-08.
Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.
Bousquet L, Pruvost A, Guyot A, Farinotti R, Mabondzo A
Antimicrob Agents Chemother. 2008; 53(3):896-902.
PMID: 19075072
PMC: 2650525.
DOI: 10.1128/AAC.00733-08.
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay K, Durand-Gasselin L, Brignolo L, Ray A, Abel K, Cihlar T
Antimicrob Agents Chemother. 2008; 52(9):3144-60.
PMID: 18573931
PMC: 2533487.
DOI: 10.1128/AAC.00350-08.
High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers.
Durand-Gasselin L, Pruvost A, Dehee A, Vaudre G, Tabone M, Grassi J
Antimicrob Agents Chemother. 2008; 52(7):2555-63.
PMID: 18426897
PMC: 2443928.
DOI: 10.1128/AAC.01130-07.
